Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

Survey on Anemia Therapy in Participants With Chronic Kidney Disease (CKD) Not on Dialysis

Completed

Conditions: Chronic Kidney Diseases

Interventions: Drug: ESA
Other: Satisfaction Survey Questionnaire

First Posted Date: 2014-09-12

Last Posted Date: 2017-03-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 196

Registration Number: NCT02238067

Locations: 🇮🇱
Clalit- New Savyon Clinic, Ganey Tikva, Israel
🇮🇱
Kaplan Medical Center; Nephrology and Hypertension Services, Rehovot, Israel
🇮🇱
Clalit - Diabetic HaMoshava South Clinic, Jerusalem, Israel

and more 4 locations

Local, Non-Interventional Study of RoActemra (Tocilizumab) in Poland (ACT-POL): First-Line Treatment in Routine Clinical Practice of Participants With Rheumatoid Arthritis (RA)

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab

First Posted Date: 2014-09-09

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 102

Registration Number: NCT02234960

A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: Atezolizumab
Drug: Obinutuzumab
Drug: Tazemetostat

First Posted Date: 2014-08-20

Last Posted Date: 2020-01-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 96

Registration Number: NCT02220842

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Sloan Kettering Cancer Center, New York, New York, United States
🇫🇷
Hôpital Saint-Louis, Paris, France

and more 12 locations

A Phase 1, Randomized, Double-blind, Placebo-controlled Crossover Study of RG7314 on the Potential Regulation of Higher Brain Functions in Healthy Male Participants: Proof of Mechanism

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Placebo RD + AVP SD
Drug: RG7314 RD + AVP SD
Drug: Placebo RD + Placebo SD

First Posted Date: 2014-07-31

Last Posted Date: 2016-07-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 32

Registration Number: NCT02205073

A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology

Phase 1

Terminated

Conditions: Squamous Non-Small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: RO5479599

First Posted Date: 2014-07-30

Last Posted Date: 2017-01-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 12

Registration Number: NCT02204345

An Observational Study in Participants With Chronic Hepatitis B (CHB) Receiving Therapy With Peginterferon Alfa-2a 40 Kilodaltons (kD) (PEGASYS) - The PRO B Study

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: Peginterferon alfa-2a

First Posted Date: 2014-07-28

Last Posted Date: 2017-08-31

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 50

Registration Number: NCT02201407

Locations: 🇷🇸
Clinical Center Zemun, Belgrade, Serbia
🇷🇸
Clinic for Gastroenterology and Hepatology, Belgrade, Serbia
🇷🇸
Clinical Center Vojvodine; Clinic for Infectious Diseases; Clinic for Hematology, Novi Sad, Serbia

and more 3 locations

Effectiveness, Safety & Nurse Management Study of MabThera SC in Patients With Non-Hodgkin's Lymphoma: Real-Life Setting

Completed

Conditions: Non-Hodgkin's Lymphoma

First Posted Date: 2014-07-24

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 54

Registration Number: NCT02199288

A Phase 1 Study of RO6806127 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Placebo
Drug: RO6806127

First Posted Date: 2014-07-22

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 37

Registration Number: NCT02196636

A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Trastuzumab
Drug: Paclitaxel
Drug: Docetaxel

First Posted Date: 2014-07-18

Last Posted Date: 2019-06-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 90

Registration Number: NCT02194166

Locations: 🇧🇾
State Inst N.N. Alexandrov Republican Scientific & Practical Centre of Oncology & Medical Radiology, A/g Lesnoy, Minsk Region, Belarus
🇰🇿
Oncology centre of Astana; Chemotherapy department, Astana, Kazakhstan
🇧🇾
Healthcare Institution "Brest Regional Oncologic Dispensary", Brest, Belarus

and more 4 locations

Comparative Bioavailability Study of Film-coated Tablet and Granule Formulations of RG1662

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: RG1662 tablet
Drug: RG1662 granules

First Posted Date: 2014-07-18

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 18

Registration Number: NCT02194244

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy